CLICK HERE TO PARTICIPATE IN SARP Emory

Investigators at The Cleveland Clinic, Emory University and The University of Virginia lead a collaborative effort to study the reducing and oxidizing chemistry in the airways of adults and children with severe asthma. Studies reveal that biochemical disorders are characteristic of severe asthma and include: (1) impaired regulation of airway acidity, (2) loss of antioxidant capacity, and (3) loss of beneficial chemical forms of nitric oxide. The Emory site has focused on severe asthma in pediatric-age patients, so as to understand the origin of severe asthma early in life, and how it changes over time. The overall goal of the Cleveland Clinic-Emory-UVA consortium is to discover and test new treatments for severe asthma, which target the airway redox chemical pathways.


Emory University
Anne Fitzpatrick, PhD (co-investigator)

Interested in Participating in SARP?

You will likely qualify for participation in SARP as a severe asthmatic if you:
1.    Have been diagnosed with asthma by a physician
2.    Require high  or continuous doses of asthma medications, such as Advair, Symbicort, prednisone or medrol
3.    Still have asthma symptoms on a regular basis
4.    Have had frequent or severe exacerbations of asthma (requiring prednisone,  ER visits, hospitalizations)
5.    Are not currently smoking and have smoked less than 5-10 years total
6.    Are between the ages of 6 yrs and 75 yrs of age

You may also qualify for participation in SARP as a “comparative” patient with mild asthma.     Similarly, you must be diagnosed with asthma, be between 6 and 75 yrs of age and not be currently smoking or have smoked for more than 5-10 yrs

CLICK HERE TO PARTICIPATE IN SARP Cleveland Clinics Cleveland OH & Satellites